Can You Still Get Compounded Semaglutide? The 2026 Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Compounded semaglutide remains available through licensed 503A pharmacies in 2026 for patients with documented individualized clinical reasons
• The February 21, 2025 FDA shortage resolution ended broader compounding pathways but did not affect the 503A patient-specific framework
• Telehealth platforms continue to operate in this space with more rigorous intake processes than during the shortage period
• Brand alternatives have improved significantly, with NovoCare Wegovy Self-Pay at $499/month providing a real new option
• Non-licensed sources (research-chemical websites, gray-market peptide vendors) are not legitimate and carry substantial safety risk

Direct answer

Yes, compounded semaglutide remains available in 2026 through licensed 503A pharmacies for patients with documented clinical justification. The pathway narrowed after the FDA resolved the semaglutide shortage on February 21, 2025, ending shortage-based compounding. Patient-specific compounding under Section 503A continues for legitimate clinical reasons including allergen sensitivities, dose individualization, and formulation requirements.

Table of contents

1. The state of compounded semaglutide access
2. What the February 2025 shortage resolution actually changed
3. The legitimate intake-to-shipment pathway
4. Eligibility: who qualifies for compounded vs brand
5. Costs in 2026
6. How to verify a legitimate compounding source
7. Common scenarios and how they resolve
8. Brand alternatives that improved in 2025
9. The contrary view: arguments to skip compounded entirely
10. Decision framework
11. FAQ
12. Sources

The state of compounded semaglutide access

Three years after the shortage peaked, the access picture is different but not closed:

• Licensed 503A pharmacies continue to compound semaglutide for individual patients under valid prescriptions
• Telehealth platforms partner with vetted 503A networks; the platform handles consultation and the pharmacy fills the prescription
• The clinical justification requirement is now substantive, not perfunctory. Prescribers document specific reasons for compounded preparation vs brand
• The 503B outsourcing facility pathway, which had supplied much of the high-volume compounded semaglutide market, ended with the shortage resolution
• Brand alternatives became more accessible in parallel, especially NovoCare Wegovy Self-Pay at $499/month

What the February 2025 shortage resolution actually changed

The FDA's February 21, 2025 decision had specific consequences:

Ended:

• 503B production of compounded semaglutide for office stock
• Shortage-based 503A compounding without individualized clinical justification
• API import allowances tied to shortage authority
• The "anyone can get compounded because it's on the shortage list" pathway used by many platforms during 2022-2024

Did not end:

• The Section 503A federal statute, which authorizes patient-specific compounding
• Legitimate clinical situations that have always supported 503A compounding
• State pharmacy board authority over compounding operations
• Prescriber discretion to write patient-specific compounded prescriptions when clinically indicated

The shift is real but not catastrophic. Patients who genuinely need compounded preparation for clinical reasons still have access. Patients who chose compounded purely on cost have a substantially improved brand alternative.

The legitimate intake-to-shipment pathway

At FormBlends and similar platforms operating in compliance with the post-shortage framework, the pathway typically looks like:

1. Initial assessment. Clinical intake covers medical history, weight history, comorbidities, prior medications, and current health status. A licensed prescriber reviews the case.
2. GLP-1 eligibility. The prescriber determines whether semaglutide therapy is appropriate at all (BMI criteria, comorbidity status, contraindications).
3. Brand consideration. If semaglutide is appropriate, the prescriber evaluates whether brand Wegovy or Ozempic fits the patient. This includes assessing insurance coverage and self-pay options like NovoCare.
4. Compounded justification. If brand cannot serve the patient for a documented clinical reason, the prescriber documents the specific reason and writes a compounded prescription. The reason must be substantive: allergen sensitivity, dose individualization, etc.
5. 503A pharmacy fulfillment. A licensed 503A pharmacy compounds the patient-specific prescription under USP 797 standards and ships under cold chain.
6. Ongoing oversight. The prescriber reviews progress at regular intervals, including the continued clinical justification for compounded vs brand.

Eligibility: who qualifies for compounded vs brand

The semaglutide clinical criteria (BMI 30+, or BMI 27+ with comorbidity, for obesity; type 2 diabetes for Ozempic) apply across brand and compounded. The differentiator is the clinical reason for compounded specifically.

Compounded may be clinically appropriate when:

• The patient has documented sensitivity to specific inactive ingredients in brand Ozempic, Wegovy, or Rybelsus (such as phenol, propylene glycol, or specific buffer concentrations)
• The patient requires an intermediate titration dose not commercially available (such as 0.125 mg or 0.375 mg between standard steps)
• The patient needs a different concentration to manage injection volume tolerability
• The patient has documented sensitivity to common preservatives, requiring a preservative-free formulation
• Other documented clinical reasons that the commercial formulation cannot accommodate

Brand is typically the appropriate path when:

• The patient meets criteria without specific intolerance issues
• Insurance coverage makes brand affordable (most diabetes coverage; varies for obesity)
• NovoCare Wegovy Self-Pay at $499/month is workable for the patient's budget
• The patient values the FDA-approved status and trial-backed dosing of the commercial product

Costs in 2026

Pricing has shifted across both categories.

Option	Typical Monthly Cost
Compounded semaglutide (503A) with documented clinical reason	$200-$400
Brand Wegovy through NovoCare Self-Pay	$499
Brand Wegovy through commercial insurance with savings card	$25-$200, varies
Brand Ozempic for type 2 diabetes (commercial insurance)	$25 with savings card, up to several hundred without
Brand Wegovy retail pharmacy (uninsured, no self-pay program)	$1,300+

The cost gap between compounded and brand self-pay is substantially smaller in 2026 than during the shortage. For some patients, that changes the calculus entirely.

How to verify a legitimate compounding source

Verification steps:

• Named pharmacy partner. The platform identifies its 503A pharmacy. The pharmacy has a physical U.S. address and an active state license.
• State board verification. Each state pharmacy board publishes a license lookup. Confirm active 503A licensure.
• Inspection records. Recent state inspections without significant deficiencies indicate good operation.
• USP 797 compliance. Sterile compounding requires USP 797. The pharmacy should describe its program.
• API documentation. Semaglutide API should come from an FDA-registered supplier with chain-of-custody documentation.
• Quality testing. Best-practice pharmacies test finished product through third-party labs for sterility, endotoxin, and potency.

If a source cannot answer these questions or evades them, the source is likely not legitimate.

Common scenarios and how they resolve

Scenario 1: Patient on compounded for two years wants to continue. Resolution: Confirm with prescriber that the chart documents a clinical reason. If yes, continued access is straightforward. If no, develop documentation or transition to brand.

Scenario 2: Patient new to GLP-1s, wants compounded for cost reasons. Resolution: Compare NovoCare Wegovy Self-Pay at $499 to compounded pricing at the patient's dose. The brand option may be more attractive than expected. Compounded without clinical justification is not appropriate.

Scenario 3: Patient develops injection-site reactions on brand Wegovy. Resolution: The prescriber can document the reaction and may transition to compounded with a different formulation profile. This is a legitimate 503A use case.

Scenario 4: Patient was on compounded through a 503B-supplied platform that closed. Resolution: Transition to a 503A-partnered platform or to brand Wegovy. Many platforms made this shift in early 2025.

Scenario 5: Patient saw an online ad for compounded semaglutide at $99/month. Resolution: Avoid. Legitimate compounded pricing is in the $200-$400 range. Sources advertising substantially below that are typically counterfeit or operating outside the licensed framework.

Brand alternatives that improved in 2025

The brand option got better in 2025, which affects the compounded-vs-brand calculus.

NovoCare Wegovy Self-Pay expanded to a broader patient base at $499/month across all dose strengths. This is available without insurance through participating pharmacies and direct shipping.

Insurance coverage for Wegovy expanded gradually, with more commercial plans adding obesity medication coverage. Medicare Part D and many Medicaid programs still exclude obesity-only indications, but coverage is broadening.

The Ozempic savings card continued to reduce copay for commercially insured patients with diabetes coverage to $25/month.

For some patients who chose compounded purely on cost, these brand changes make a real difference. For patients with specific clinical needs, compounded remains the appropriate option.

The contrary view: arguments to skip compounded entirely

A reasonable position: with NovoCare at $499 and improved insurance coverage, the cost-driven case for compounded has weakened. Patients should default to brand and consider compounded only for narrow situations of genuine clinical necessity.

This view argues that compounded peptide preparations introduce manufacturing variability that does not improve outcomes when brand is accessible, and that the 503A pathway was not designed for the volume of obesity-medication compounding it has supported.

The counter: 503A is settled federal law. Individual clinical circumstances do justify compounded preparation in specific cases. Even with NovoCare at $499/month, that price is significant for many patients, and the relative price of compounded matters for those budgets. The pathway should be available where clinically indicated.

Both positions have intellectual merit. The current legal framework reflects Congress's judgment. Clinical practice varies.

Decision framework

Currently on compounded semaglutide: Confirm clinical justification is documented. Continue if appropriate; consider transition if not.

New to GLP-1 therapy: Default to brand Wegovy or Ozempic. Compounded is appropriate when individualized clinical needs exist.

Cost-focused: Compare NovoCare $499 to compounded pricing at your dose. The gap may be smaller than expected.

Specific intolerance to brand: Document the intolerance with your prescriber. Compounded with a different formulation profile is a legitimate option.

FAQ

Can you still get compounded semaglutide?
Yes, through 503A pharmacies with documented clinical justification.

How do I find a pharmacy that compounds semaglutide?
Most patients access through telehealth platforms that partner with 503A pharmacies.

What clinical reasons justify it?
Allergen sensitivity, dose individualization, concentration adjustments, preservative-free needs.

Is it legal to buy compounded semaglutide online?
Yes, through legitimate platforms with licensed prescribers and 503A pharmacy partners.

How much does it cost in 2026?
$200-$400/month typically; brand Wegovy NovoCare self-pay is $499/month.

Do I need a real prescription?
Yes, federal and state law require a valid prescription.

Can I get it just for weight loss?
Weight loss is the indication; the additional question is brand vs compounded preparation.

Is compounded as effective as brand?
Same active ingredient; clinical trial data applies to brand specifically.

How is it different from research peptides?
Compounded is licensed pharmacy with prescription; research peptides are non-licensed vendors without legitimate medical framework.

Will compounded semaglutide go away entirely?
Eliminating the 503A pathway requires Congressional action; no legislation pending.

Sources

1. FDA Drug Shortage List update, February 21, 2025, resolving semaglutide shortage
2. Federal Food, Drug, and Cosmetic Act Section 503A, 21 U.S.C. § 353a
3. Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, March 2021 (STEP 1)
4. USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations
5. Novo Nordisk NovoCare Wegovy Self-Pay program announcement
6. FDA Guidance on compounding under Section 503A
7. Wegovy FDA prescribing information
8. Ozempic FDA prescribing information
9. National Association of Boards of Pharmacy compounding standards
10. Novo Holdings Catalent acquisition announcement, December 2024
11. FDA enforcement actions against non-licensed compounding sources, 2024-2025
12. Endocrine Society Clinical Practice Guideline on Obesity, 2023

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed clinicians and 503A compounding pharmacies. We are not a pharmacy or a medical practice. Prescribing, compounding, and dispensing decisions rest with licensed professionals.

Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. Not regulatorily equivalent to Ozempic, Wegovy, or Rybelsus. STEP trial data applies to brand product specifically.

Results Disclaimer. Individual outcomes vary. STEP 1 reported a 14.9% mean weight loss at week 68 with semaglutide 2.4 mg weekly. Your result depends on dose, adherence, baseline weight, and individual response.

Trademark Notice. Ozempic, Wegovy, Rybelsus, and NovoCare are trademarks or service marks of Novo Nordisk A/S. FormBlends is independent.